Eric Schmidt

Stock Analyst at Cantor Fitzgerald

(0)
# 4908
Out of 5,240 analysts
40
Total ratings
11.54%
Success rate
-30.64%
Average return
17 Stocks
Name Action Price Target Current % Upside Ratings Updated
Incyte
Reiterates: Neutral
n/a
n/a n/a 6 Jan 10, 2025
Agios Pharmaceutical...
Reiterates: Overweight
n/a
n/a n/a 4 Dec 18, 2024
Tango Therapeutics
Reiterates: Overweight
n/a
n/a n/a 3 Dec 5, 2024
Alumis
Reiterates: Overweight
n/a
n/a n/a 3 Nov 14, 2024
Bicara Therapeutics
Initiates Coverage On: Overweight
n/a
n/a n/a 1 Oct 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
96 96
28.52 236.61% 4 Sep 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 2 Sep 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 3 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
n/a
n/a n/a 2 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
292 292
145.32 100.94% 3 Sep 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 3 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
n/a
n/a n/a 1 May 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
370
419.49 -11.8% 1 Oct 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Oct 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
n/a
n/a n/a 1 Jul 10, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
31
n/a n/a 1 Jun 12, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
n/a
n/a n/a 1 May 30, 2017